Evidence map›Paper›PMID 24390323›Full record

ArticleJournal of virology2014

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Maria Salgado, Michael D Swanson, Christopher W Pohlmeyer, Robert W Buckheit, Jin Wu, Nancie M Archin, Thomas M Williams, David M Margolis, Robert F Siliciano, J Victor Garcia and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. HIV Virion Capturing Liposomes for Therapeutic Vaccination.bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Maria SalgadoDepartment of Medicine, Center for AIDS Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michael D Swanson
Christopher W Pohlmeyer
Robert W Buckheit
Jin Wu
Nancie M Archin
Thomas M Williams
David M Margolis
Robert F Siliciano
J Victor Garcia
Joel N Blankson
University of North Carolina at Chapel Hill · USJohns Hopkins Medicine · USJohns Hopkins University · USUniversity of New Mexico · USUniversitat Autònoma de Barcelona · ES

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOELK, CHRISTOPHER H · 2011 to 2015
$39.5M
BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Vaginal/Rectal HIV Transmission ModelR01AI073146 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA-MARTINEZ, J. VICTOR · 2007 to 2016
$4.8M
Next Generation Pre-exposure ProphylaxisR01AI096138 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2011 to 2014
$3.5M
HIV Latency, Epigenetics, and TherapeuticsR01DA030156 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2010 to 2014
$3.0M
CD8+ T cell mediated inhibition of HIV-1 replication in Elite SuppressorsR01AI080328 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2009 to 2012
$1.3M
CD8+ T cell mediated inhibition of HIV-1 replication in Elite SuppressorsR56AI080328 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2014 to 2014
$405k
Mechanisms of Cell-associated HIV Transmission in Humanized MiceF32AI100775 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SWANSON, MICHAEL D · 2012 to 2013
$101k
NCATS NIH HHS UL1 TR001079NIAID NIH HHS AI073146NIAID NIH HHS AI080328NIAID NIH HHS AI096113NIAID NIH HHS AI096138NIAID NIH HHS AI100775NIAID NIH HHS F32 AI100775NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI073146NIAID NIH HHS R01 AI080328NIAID NIH HHS R01 AI096138NIAID NIH HHS R56 AI080328NIAID NIH HHS U19 AI096113NIDA NIH HHS 5R01DA030156NIDA NIH HHS R01 DA030156NIGMS NIH HHS T32 GM007445NIGMS NIH HHS T32 GM008752
6 · The paper itself

Abstract

unlabelledElite controllers or suppressors (ES) are HIV-1-infected patients who maintain undetectable viral loads without antiretroviral therapy. The mechanism of control remains unclear, but the HLA-B*57 allele is overrepresented in cohorts of these patients. However, many HLA-B*57 patients develop progressive disease, and some studies have suggested that infection with defective viruses may be the cause of the lack of high levels of virus replication and disease progression in ES. We therefore performed a comprehensive comparative in vivo and in vitro characterization of viruses isolated from well-defined ES. For this purpose, we first performed full-genome sequence analysis and in vitro fitness assays on replication-competent isolates from HLA-B*57 ES and HLA-B*57 chronic progressors (CPs). Under our experimental conditions, we found that isolates from ES and CPs can replicate in vitro. However, since inherently these assays involve the use of unnaturally in vitro-activated cells, we also investigated the replication competence and pathogenic potential of these HIV isolates in vivo using humanized BLT mice. The results from these analyses demonstrate that virus isolates from ES are fully replication competent in vivo and can induce peripheral and systemic CD4 T cell depletion. These results provide the first direct in vivo evidence that viral fitness does not likely determine clinical outcome in HLA-B*57 patients and that elite suppressors can control replication-competent, fully pathogenic viruses. A better understanding of the immunological bases of viral suppression in ES will serve to inform novel approaches to preventive and therapeutic HIV vaccine design. IMPORTANCE: Elite suppressors are HIV-1-infected patients who have undetectable levels of viremia despite not being on antiviral drugs. One of the most fundamental questions about this phenomenon involves the mechanism of control. To address this question, we isolated virus from elite suppressors and from HIV-1-infected patients who have the usual progressive disease course. We compared how well the isolates from the two groups of patients replicated in culture and in humanized mice. Our results suggest that elite suppressors are capable of controlling HIV-1 due to the possession of unique host factors rather than infection with defective virus.

Indexed as

Virus ReplicationAmino Acid SequenceAnimalsCD4-Positive T-LymphocytesFemaleGenetic VariationHIV-1HIV InfectionsHIV Long-Term SurvivorsHLA-B AntigensHumansLymphocyte DepletionMaleMiceMice, Inbred NODMolecular Sequence DataHLA-B57 antigenHLA-B Antigens

Identifiers

PMID24390323
PMCPMC3957943
OpenAlexW2018270291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.